Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan

 Roche Concludes the License Agreement with Chugai for AT-527 to Treat COVID-19 in Japan

” Roche Presents Results of Hemlibra Reinforcing the Long-Term Benefits for Hemophilia A at ASH 2020″

Shots:

  • Chugai gets exclusive development and commercializing rights for AT-527 in Japan
  • Earlier, Roche and Atea collaborated to jointly develop AT-527. If approved, Atea to distribute AT-527 in the US and Roche will be responsible for global manufacturing and distribution outside the US
  • AT-527 is an investigational, oral, purine nucleotide prodrug, currently being evaluated in a P-II study in patients with moderate COVID-19 requiring hospitalization and patients with mild to mod. COVID-19 who are not hospitalized. A P-III study is expected to start in the H1’21

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Switzerland Global Enterprise

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post